SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the closing of a previously announced registered underwritten secondary public offering of its common stock by certain of its stockholders (the “Selling Stockholders”). The Selling Stockholders sold a total of 10 million shares of Catalent’s common stock at a price to the public of $24.85 per share. Catalent did not sell any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Stockholders.

Goldman, Sachs & Co acted as underwriter for the offering.